Business
History
Highlights and milestones from Alvogen’s history
Scroll through important milestones and highlights from our history, from 2009 until today.
1st
01
2009
This year Alvogen was founded on the strong foundation of Norwich Pharmaceutical services, with a 130-year history.
People
Robert Wessman joins Alvogen as Chairman and CEO
Business
Alvogen launches Asia operations
Products
Alvogen acquires R&D capabilities from from Par Pharmaceutical
2nd
02
2010
International expansion started. Foundation laid in major fields of operation.
Business
Expansion in Eastern Europe - office opened in Bucharest Romania
People
Top executives appointed
Products
R&D center opens in Pinebrook, NJ
US pipeline
Alvogen teams up with Orchid in India
Business
Alvogen expands its operations in India
Business
Alvogen acquires Keri pharma
3rd
03
2011
International expansion continues. First products sold in the US market.
Products
First products launched in Thailand market
Products
First-to-file on Tamiflu
Business
Alvogen opens new offices including Poland, Russia, Croatia, Macedonia, Albania and Kazakhstan
Pure Iceland
New OTC line launched in China
Business
US team hits record in sales
Norwich Clinical Services
NCS inaugurates a new clinical facility in India
Academic collaboration
Partnerships with MIT and Columbia University
4th
04
2012
Alvogen enters the APAC region through strategic acquisitions. Biosimilar partnership signed with Hospira.
India
CRO built in Bangalore
CEE region
Packaging Center built in Serbia
Biosimilar partnership
Biosimilar partnership signed with Hospira - first biosimilars sold in CEE
Products
First generic products sold in the APAC market
Awards
Alvogen US received DIANA merit award
APAC
Alvogen aquires majority in Kunwha
Awards
Norwich Pharmaceuticals received CMO leadership Award
5th
05
2013
Alvogen recognized for a dynamic growth in the US market and further steps taken in the development of the APAC platform.
Awards
Diana Award received
Awards
Alvogen received CMO Leadership Awards for the second year running
Business
Aquisition of Labormed in Romania
Investment
Groundbreaking of a new biopharmaceuticals plant
Business
Alvogen acquires Naprelan® in the US
Business
Alvogen becomes the majority shareholder in Lotus Pharmaceuticals
6th
06
2014
Biosimilar platform strengthened with new monoclonal antibodies launched in the CEE region. Alvogen aquires Korean Dream pharma.
Biosimilars
First to market with Inflectra in Europe with Hospira
Events & exhibitions
Alvogen scores high at CPhI 2014 for the third year in a row
Awards
Alvogen wins Diana "Oscar" for the third consecutive year
Awards
Alvogen receives double awards from the Generic bulletin
Business
Pamplona acquires stake in Alvogen
Business
Alvogen aquires Korean Dream pharma
7th
07
2015
Business
Dream pharma and Kunwha pharmaceuticals become Alvogen Korea
Awards
Alvogen was honored as a Generic Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors
Products
Alvogen lauches the first generic Exelon® patch in the United States
Awards
Alvogen won EMEA company of the year awards from Generics Bulletin
Business
CVC capital partners leads investment consortium to acquire controlling stake in Alvogen
8th
08
2016
Kick-off
Alvogen held its annual Kick-off in Phuket, Thailand. 115 company excecutives attended to discuss strategies and objectives
Business
Alvogen expands US business agreement signed to acquire County Line Pharmaceuticals
Academics
Alvogen in Harvard case study
Products
Alvogen announced the launch of the first generic equivalent of ZoladexTM in Central and Eastern Europe
Business
Alvotech opens state-of-the-art biosimilar facility in Iceland
Products
Alvogen launches first generic equivalent of Copaxone(TM) in Europe
Products
Alvogen launches the first generic equivalent to Tamiflu® capsules in the United States
9th
09
2017
Successful events and strategic product launches.
Kick-off
Global Kick-off in Malta
Products
Alvogen first to market with generic equivalent to Tamiflu® powder for oral suspension
Products
First approval for glatiramer acetate in Europe
Events & exhibitions
CPhI in Frankfurt was a great success for Alvogen
Products
Alvogen subsidiary confirms ANDA filing and patient challenge for generic Revlimid®
Products
Alvogen adds Qsymia to its anti-obesity portfolio in Korea
Business
Alvogen acquires Omega Bittner, a Russia-based pharmaceutical firm, and significantly strengthens the regions portfolio
10th
10
2018
Successful partnerships
Kick Off
Global Kick-off in Costa Rica
Products
Patent dispute resolved as U.S. courts clear the way for Alvogen’s production of Suboxone
Awards
European CEO Magazine named Alvogen’s Robert Wessman as the Best CEO in the Pharmaceuticals Industry
Products
Exclusive partnership for commercialization of Prestige BioPharma's Trastuzumab biosimilar in CEE
Products
An exclusive partnership and distribution deal with Theramex
Products
Alliance with Pfenex for the commercialization of its teriparatide biosimilar
Products
First to obtain European approvals for Generic Lenalidomide
Business
Alvogen: Scaling Entrepreneurship, A HBS case study
11th
11
2019
Kick-off
Global Kick-off in Iceland
Products
Alvogen and Lotus launch the first generic equivalent to Revlimid™ capsules in selected European countries
Products
Alvogen launches generic equivalent to Suboxone®
Business
Alvogen upgrades its oncology manufacturing facility in Taiwan
Awards
Lotus pharmaceuticals collects outstanding company award
Products
Alvogen and Covis pharma make distribution agreement for a leading asthma medicine
Business
Alvogen divests CEE business to Zentiva
APAC